Do thrombophilic gene mutations have a role on thromboembolic events in cancer patients?

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 3, 2012, Pages

  Ozkan, Metin ^a   Sivgin, Serdar ^a   Kocyigit, Ismail ^a   Emirogullari, Funda ^a   Dikilitas, Mustafa ^a   Kaynar, Leylagul ^a   Ozkul, Yusuf ^a   Er, Ozlem ^b  

^a ERCIYES UNIVERSITY   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Cancer; Mutation; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; GENOMIC DNA; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTHROMBIN; THROMBOEMBOLISM; THROMBOPHILIA; YOUNG ADULT;

EID: 84865416633     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01536.x     Document Type: Article

References (29)

1. Levine MN, Lee AY, Kakkar AK. From trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 2003; 1: 1456-63.
2. Altinbas M, Coskun HS, Er O etal. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-71.
3. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
4. Paskauskas S, Pundzius J, Barauskas G. Venous thromboembolism and prophylaxis in cancer patients. Medicina (Kaunas) 2008; 44: 175-81.
5. Er O, Zacharski L. Management of cancer-associated venous thrombosis. Vasc Health Risk Manag 2006; 2: 351-6.
6. Ramacciotti E, Wolosker N, Puech-Leao P etal. Prevalence of Factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 2003; 15: 171-4.
7. Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost 2008; 34: 282-5.
8. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
9. Haim N, Lanir N, Hoffman R etal. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-6.
10. Otterson GA, Monahan BP, Harold N etal. Clinical significance of the FV: Q506 mutation in unselected oncology patients. Am J Med 1996; 101: 406-12.
11. Ravin AJ, Edwards RP, A Krohn M etal. The Factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol 2002; 100: 1285-9.
12. Sousou T, Khorana A. Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie 2009; 29: 121-4.
13. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-10.
14. Mandalà M, Curigliano G, Bucciarelli P etal. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15: 590-3.
15. Eroglu A, Kurtman C, Ulu A etal. Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis. J Thromb Haemost 2005; 3: 1323-34.
16. Eroglu A, Ulu A, Cam R etal. Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis 2007; 23: 31-4.
17. Eroglu A, Egin Y, Cam R, Akar N. The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis. Ann Hematol 2009; 88: 73-6.
18. Pihusch R, Danzl G, Scholz M etal. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002; 94: 3120-6.
19. Lipay NV, Dmitriev VV, Borisenok MB. Thrombotic complications during cancer treatment in children. Exp Oncol 2007; 29: 231-5.
20. Sifontes MT, Nuss R, Hunger SP etal. The Factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997; 96: 484-9.
21. Kennedy M, Andreescu AC, Greenblatt MS etal. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol 2005; 128: 386-8.
22. Sciacca FL, Ciusani E, Silvani A etal. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 2004; 10: 1312-7.
23. Green D, Maliekel K, Sushko E etal. Activated protein-C resistance in cancer patients. Haemostasis 1997; 27: 112-8.
24. Akar N, Yilmaz E, Akar E etal. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV 1691 G-A. Thromb Res 2000; 97: 227-30.
25. Barcellona D, Fenu L, Cauli C etal. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. Thromb Haemost 2003; 90: 1061-4.
26. Eroglu A, Ulu A, Akar N. Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis. J Thromb Thrombolysis 2006; 22: 111-2.
27. Jacques PF, Bostom AG, Williams RR etal. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
28. Schiavon G, Vincenzi B, Santini D etal. Recurrent thrombophlebitis in a colon cancer patient with C677T heterozygous genotype for MTHFR treated with 5-fluorouracil-based adjuvant chemotherapy. Chemotherapy 2004; 50: 194-5.
29. Murtaugh MA, Curtin K, Sweeney C etal. Dietary intake of folate and co-factors in folate metabolism, MTHFR polymorphisms, and reduced rectal cancer. Cancer Causes Control 2007; 18: 153-63.